The living brain and Alzheimer's disease [23-01-2003]

The Living Brain and Alzheimer's Disease
Paris, March 17, 2003

Preliminary Program

Scientific Committee : Bradley Hyman (Massachusetts General Hospital, Boston)
Jean-François Demonet (Inserm U.455, Hôpital Purpan, Toulouse)
Yves Christen (Fondation IPSEN, Paris)

8.00 a.m. Registration : Espace Charles Louis Havas
136, Avenue Charles de Gaulle, 92200 Neuilly sur Seine

8.30 a.m. Yves Christen, Bradley Hyman, Jean-François Demonet Welcoming remarks and introduction

8.45 a.m. Charles Duyckaerts (Hôpital de la Salpêtrière, Paris) : Neuropathology : terminus ad quem
9.15 a.m. Marilyn Albert (Massachusetts General Hospital, Charlestown) : Title to be submitted
9.45 a.m. Christoph Hock (University of Zurich) : CSF biomarkers for diagnosis of Alzheimer's disease

10.15 a.m. Posters and Coffee-break

10.45 a.m. Bradley Hyman (Massachusetts General Hospital, Boston) : Imagining the natural history of Alzheimer's disease
11.15 a.m. Brian Bacskai (Massachusetts General Hospital, Charlestown) : In vivo imaging of Alzheimer pathology in transgenic mice using multiphoton microscopy
11.45 a.m. Thomas Wisniewski (NYU School of Medicine, New York) : In vivo MRI of amiloid plaques in Alzheimer's disease model mice

12.15 a.m. Posters and Lunch

1.45 p.m. William Klunk (University of Pittsburgh) : Development of benzothiazole amyloid-imaging agents
2.15 p.m. Bengt Langstrom (Uppsala University, PET Centre, Uppsala) : participation to be confirmed
2.45 p.m. Clifford Jack (Mayo Clinic, Rochester) : MR measures of disease stage and progression in Alzheimer's disease

3.15 p.m. Posters and Coffee-break

3.45 p.m. Nick Fox (National Hospital for Neurology / Neurosurgery, London) : Measuring progression in Alzheimer's disease using serial MRI : 4D MRI
4.15 p.m. Eric Reiman (University of Arizona, Phoenix) : Brain imaging studies of cognitively normal persons at genetic risk for Alzheimer's disease
4.45 p.m. Paul Thompson (UCLA School of Medicine, Los Angeles) : Dynamics of gray matter loss in Alzheimer's disease, mapped with a population based brain atlas
5.15 p.m. Bradley Hyman (Massachusetts General Hospital, Boston) : Concluding remarks